Media Coverage
- March 2, 2021: NDR Visite - TV Segment: Corona-Forschung: neue Medikamente gegen das Virus?
- January 22, 2021: Bayern 2 (Bayerischer Rundfunk) - Podcast: Corona-Medikamente - Wirkstoff in der zweiten Testphase
- December 10, 2020 - EIB: Treat, test, vaccinate
- vfa Report: Therapeutische Medikamente gegen die Coronavirusinfektion Covid-19
- October 20, 2020 - European Biotechnology: Atriva Therapeutics gets €24m from EIB
- August 12, 2020 - Transkript: 8,6 Mio. Euro für Atrivas Corona-Wirkstoff
- July 15, 2020 – European Biotechnology Magazine Summer 2020: Antiviral drug for pandemic preparedness (page 29)
- June 5, 2020 – Genetic Engineering & Biotechnology News: Atriva Therapeutics – ATR-002
- June 2, 2020 – Pharmazeutische Zeitung: MEK-Inhibitor im Test gegen Covid-19
- June 2020 – Nature Biopharma Dealmakers: Atriva Therapeutics: transforming antiviral therapies
- May 4, 2020 - Capital: Wirkt das? Biotech gegen Corona
- March 24, 2020 – ARD: Kampf um Corona-Medikamente
- February 6, 2020 – Handelsblatt: Wie Pharmakonzerne an Mitteln gegen das Coronavirus forschen
- January 28, 2020 – SCRIP: Atriva fast tracks antiviral candidate as coronavirus arrives in Germany
- January 28, 2020 – Der Tagesspiegel: Therapieansätze gegen das Wuhan-Virus. Deutsche Forscher entwickeln Impfstoffe gegen Coronaviren
- July 7, 2019 – LABO: Vier Unternehmen mit "Biomarker Validation Award" ausgezeichnet
- March 8, 2019 – Labiotech: Flu resistant to antivirals? This biotech has a drug for that
- January 4, 2019 – Wirtschaftswoche: 1,25 Mio. Euro für den Kampf gegen Viren
- 2017 – New article published in "Platform Life Sciences" presenting ATRIVA approach
- 2017 – Interview with ATRIVA CEO during BIO-Europe Spring(R) 2017
- 2017 – Nature: Host with the most: Targeting host cells instead of pathogens to fight infectious disease